Favorable PCAC votes would move DSIP, Epitalon, and Semax toward the 503A Bulks List and a regulated compounding route.
The biggest Day 2 story goes beyond three vote totals. It is about what favorable recommendations could unlock for peptide access.
Emideltide (DSIP), Epitalon, and Semax each have separate free-base and acetate questions on July 24.
A route through the 503A Bulks List
Favorable recommendations would move the three peptides forward for FDA consideration on the Section 503A Bulks List.
That list provides the federal framework for certain patient-specific compounded prescriptions made from bulk drug substances.
Licensed pharmacies instead of grey-market products
The practical advantage is clear: existing peptide demand can move toward licensed compounding pharmacies, patient-specific prescriptions, and documented quality systems.
That was the central access argument behind the favorable Day 1 votes.
What a favorable DSIP vote would mean
Emideltide would move forward as the Day 2 peptide tied most directly to sleep, narcolepsy, and opioid-withdrawal interest.
What a favorable Epitalon vote would mean
Epitalon would bring one of the peptide world's biggest longevity followings into the 503A Bulks List process.
What a favorable Semax vote would mean
Semax would move the meeting's cognition and neurological story toward a regulated compounding route.
Day 1 created the model
BPC-157, KPV, and TB-500 all received favorable committee results. Friday gives PCAC the opportunity to extend that momentum across sleep, longevity, and cognition.
Follow the outcome on Rebody's live PCAC peptide tracker.
503A Day 2 FAQ
What would favorable PCAC votes do?
They would move DSIP, Epitalon, and Semax forward for FDA consideration on the 503A Bulks List.
How many Day 2 questions are scheduled?
Six questions: free-base and acetate votes for each of three peptides.
Which Day 1 peptides received favorable results?
BPC-157, KPV, and TB-500.